Artemis Therapeutics competitorsClear all

Artemis Therapeutics's top competitors include Biogen, Inovio Pharmaceuticals, MyoKardia and Athersys.
Artemis Therapeutics
Artemis Therapeutics
Artemis Therapeutics (formerly known as New York Global Innovations) is a biopharmaceutical company that engages in the development of agents for the prevention and treatment of severe and potentially life-threatening infectious diseases.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Inovio Pharmaceuticals
Inovio Pharmaceuticals
Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid immunotherapies and vaccines.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Founding Date
Founding Date
1997
Founding Date
1978
Founding Date
1979
Founding Date
2012
Founding Date
1995
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New York, US HQ
San Diego, US
Locations
Cambridge, US HQ
Vicente López, AR
Macquarie Park, AU
Wien, AT
Machelen, BE
São Paulo, BR
Mississauga, CA
see more
Locations
Plymouth Meeting, US HQ
San Diego, US
San Diego, US
Locations
South San Francisco, US HQ
Brisbane, US
Locations
Cleveland, US HQ
Canton, US
Employees
Employees
1
Employees
7,4005% decrease
Employees
2811% increase
Employees
23542% increase
Employees
8311% increase
Valuation ($)
Valuation ($)
824.6 k
Valuation ($)
42.4 b
Valuation ($)
2 b
Valuation ($)
12 b
Valuation ($)
425.1 m
Twitter followers
Twitter followers
51
Twitter followers
36.4 k
Twitter followers
17.2 k
Twitter followers
1.2 k
Twitter followers
2 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
19
Number of tweets (last 30 days)
6
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
4
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
21.5
Average likes per tweet (last 30 days)
150.8
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
21.3
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
94.74%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
229976
Alexa Website Rank
254464
Alexa Website Rank
219966
Alexa Website Rank
239431
Alexa Website Rank
175823
Employee Rating
Employee Rating
N/A
Employee Rating
4.1
Employee Rating
3.5
Employee Rating
4.2
Employee Rating
4

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$14.4b (FY, 2019)
Revenue (est.)
$4.1m (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
$5.6m (FY, 2019)
Net income
Net income
($121k) (FY, 2019)
Net income
$5.9b (FY, 2019)
Net income
($120.6m) (FY, 2019)
Net income
($276.2m) (FY, 2019)
Net income
($44.6m) (FY, 2019)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
21 (FY, 2019)
Patents (US)
N/A
Patents (US)
2 (FY, 2018)
Patents (US)
21 (FY, 2016)
Patents Issued
Patents Issued
N/A
Patents Issued
34 (FY, 2019)
Patents Issued
620 (FY, 2016)
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
13 (Q3, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2018)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
9 (Q3, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2018)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q3, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2018)
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 202.6m
Total funding raised
$ 98m
Total funding raised
$ 9m
For sources of this data, please see the company profile

View company profiles

Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
Inovio Pharmaceuticals
HQ
Plymouth Meeting, US
Employees
281↑ 1% increase

Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid immunotherapies and vaccines.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
83↑ 11% increase

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company